Final Flourish: Sensational Late-Breaking Abstracts

By Binod Dhakal, MD, MS Each year on the final day of the ASH annual meeting, the Late-Breaking Abstracts (LBAs) Session presents novel, substantive, and groundbreaking research that was not available in time for the standard ASH abstract submission deadline. And if...

A New Era for Sickle Cell Disease, Acute Porphyria, and More

By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...
A Disruptive Innovation?

A Disruptive Innovation?

By Binod Dhakal, MD, MS “I just want to be a normal person, doctor,” Greg said, “but that’s not an option.” Greg, 58 years old, underwent hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML) three years ago using cells from his...

Best Donor Choice: It’s in the Eye of the Beholder!

By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...

ASH Clinical Practice Guidelines Update

ASH has long recognized the need for comprehensive guidelines and in the past three years has broken ground on developing and/or updating guidelines on several disease types, including venous thromboembolism (VTE), immune thrombocytopenia (ITP), acute myeloid leukemia...